Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | MRx0518 + pembro in patients with resistance to therapy

Alex Stevenson, PhD, 4D Pharma plc, Leeds, UK, talks about the latest updates in the clinical programme for MRx0518, a single strain live biotherapeutic in development for the treatment of cancer. Currently, the first part of the Phase I/II study has been successfully completed. The second part of the study has commenced and will evaluate the clinical benefit of MRx0518 in combination with pembrolizumab in patients with acquired resistance to prior immune checkpoint therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.